Amanote Research
Register
Sign In
T-Dm1 Reduces HER2+ Breast Cancer Recurrence
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-169
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
December 12, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
T-Dm1 Aids Patients With Advanced Breast Cancer
Cancer Discovery
Oncology
P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer
The Open Breast Cancer Journal
Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer
Oncotarget
Oncology
Radio-Sensitising Effect of T-Dm1 Should Not Be Discarded for the Efficacy of Radiosurgery in the Management of Brain Metastases in Patients With HER2-positive Metastatic Breast Cancer
Journal of Neuro-Oncology
Cancer Research
Oncology
Neurology
T-Dm1, a Novel Antibody-Drug Conjugate, Is Highly Effective Against Uterine and Ovarian Carcinosarcomas Overexpressing HER2
Clinical and Experimental Metastasis
Medicine
Cancer Research
Oncology
HER2 Expression in NF1 Breast Cancer—Response
Cancer Prevention Research
Medicine
Cancer Research
Oncology
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Developing Anti-Her2 Vaccines: Breast Cancer Experience
International Journal of Cancer
Cancer Research
Oncology
